A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis

Published:2017-02-17 Issue:7 Volume:31 Page:1161-1167
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Omland S.H.¹,Habicht A.²,Damsbo P.³,Wilms J.⁴,Johansen B.⁵,Gniadecki R.¹⁶

Affiliation:

1. Department of Dermato-Venerology; Bispebjerg University Hospital; Copenhagen Denmark

2. Signifikans Aps; Vedbaek Denmark

3. Avexxin AS, c/o Department of Biology; NTNU; Norwegian University of Science and Technology; Trondheim Norway

4. Klifo A/S; Glostrup Denmark

5. Department of Biology; NTNU; Norwegian University of Science and Technology; Trondheim Norway

6. Division of Dermatology; Faculty of Medicine; University of Alberta; Edmonton Canada

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14128/fullpdf

Reference16 articles.

1. Mechanisms of disease, psoriasis;Nestle;N Engl J Med,2009

2. The long-term efficacy and safety of new biological therapies for psoriasis;Papp;Arch Dermatol Res,2006

3. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three nordic countries;Ragnarson Tennvall;Acta Derm Venereol,2013

4. Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council;Wu;J Eur Acad Dermatol Venereol,2016

5. Phospholipase A 2 inhibitors for the treatment of inflammatory diseases : a patent review (2010 - present);Magrioti;Expert Opin Ther Pat,2013

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mobile health technologies in an interventional hybrid study on actinic keratosis: Results from an early phase randomized controlled trial investigating the safety and efficacy of a cytosolic phospholipase A2 inhibitor gel in photodamaged skin;Experimental Dermatology;2024-04

2. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances;Progress in Lipid Research;2023-07

3. Interdisciplinary advances reshape the delivery tools for effective NASH treatment;Molecular Metabolism;2023-07

4. The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond;Pharmacology & Therapeutics;2023-04

5. Narciclasine inhibits phospholipase A2 and regulates phospholipid metabolism to ameliorate psoriasis-like dermatitis;Frontiers in Immunology;2023-01-04